Tumor Immunology

ACLY Inhibitor Triggers B Cell Response to Suppress Liver Tumors and Advances Toward Clinical Trials

Preclinical evidence of metabolic disruption paired with B cell immunity has prompted plans for first-in-human studies of the selective ACLY blocker.